カテゴリ： Allied Market Research, 世界, 医療/バイオ

アトピー性皮膚炎のグローバル市場（2020～2030）：生物製剤、カルシニューリン阻害剤、PDE-4阻害剤、コルチコステロイド、その他

■ 英語タイトル：Atopic Dermatitis Market By Drug Class (Biologics, Calcineurin Inhibitors, PDE-4 Inhibitor, Corticosteroids, Others), By Mode Of Administration (Topical, Injectable, Oral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2021-2031

調査会社Allied Market Research社が発行したリサーチレポート（データ管理コード：ALD23JN080）■ 発行会社/調査会社：Allied Market Research
■ 商品コード：ALD23JN080
■ 発行日：2022年9月
■ 調査対象地域：グローバル
■ 産業分野：生命科学
■ ページ数：293
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後24時間以内）
■ 販売価格オプション（消費税別）
Online Only（1名閲覧、印刷不可）USD3,570 ⇒換算￥535,500見積依頼/購入/質問フォーム
Single User（1名閲覧）USD5,730 ⇒換算￥859,500見積依頼/購入/質問フォーム
Enterprise User（閲覧人数無制限）USD9,600 ⇒換算￥1,440,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Allied Market Research社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[アトピー性皮膚炎のグローバル市場（2020～2030）：生物製剤、カルシニューリン阻害剤、PDE-4阻害剤、コルチコステロイド、その他]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

Allied Market Research社の本レポートでは、2021年に5,333.37百万ドルであった世界のアトピー性皮膚炎市場規模が2031年には22,594.44百万ドルに達し、2022年から2031年にかけて年平均15.1％成長すると予測しています。Allied Market Research社の本レポートでは、世界のアトピー性皮膚炎市場について幅広く調査し、イントロダクション、エグゼクティブサマリー、市場概要、薬物クラス別分析（生物製剤、カルシニューリン阻害剤、PDE-4阻害剤、コルチコステロイド、その他）、投与方法別分析（局所、注射、経口）、流通チャネル別分析（病院薬局、小売薬局、オンライン薬局）、地域別分析（北米、ヨーロッパ、アジア太平洋、中南米/中東・アフリカ）、企業状況、企業情報など、以下の内容を掲載しています。さらに、Sanofi SA、Novartis International AG、Bristol-Myers Squibb、Bayer AG、AbbVie Inc.、Pfizer Inc.、Astellas Pharma Inc.、Regeneron Pharmaceuticals Inc.、Arcutis Biotherapeutics、Asana Biosciences、Dermavant、Eli Lilly、Galderma、Incyte、Viatris、Leo Pharma、Otsuka Holdings Co.,Ltdなどの企業情報が含まれています。
・イントロダクション
・エグゼクティブサマリー
・市場概要
・世界のアトピー性皮膚炎市場規模：薬物クラス別分析
- 生物製剤の市場規模
- カルシニューリン阻害剤の市場規模
- PDE-4阻害剤の市場規模
- コルチコステロイドの市場規模
- その他薬物クラスの市場規模
・世界のアトピー性皮膚炎市場規模：投与方法別分析
- 局所投与における市場規模
- 注射投与における市場規模
- 経口投与における市場規模
・世界のアトピー性皮膚炎市場規模：流通チャネル別分析
- 病院薬局チャネルの市場規模
- 小売薬局チャネルの市場規模
- オンライン薬局チャネルの市場規模
・世界のアトピー性皮膚炎市場規模：地域別分析
- 北米のアトピー性皮膚炎市場規模
- ヨーロッパのアトピー性皮膚炎市場規模
- アジア太平洋のアトピー性皮膚炎市場規模
- 中南米/中東・アフリカのアトピー性皮膚炎市場規模
・企業状況
・企業情報

世界のアトピー性皮膚炎市場は、2021年に53億3337万ドルと評価され、2022年から2031年まで年平均成長率15.1%で成長して2031年には225億9444万ドルに達すると予測されています。
アトピー性皮膚炎は慢性のそう痒性炎症性皮膚疾患（下図参照）で、通常、顔（頬）、首、腕、脚に発症しますが、鼠径部や腋窩は免れます。アトピー性皮膚炎は通常、乳幼児期に発症しますが、かなりの数の成人も罹患します。アトピー性皮膚炎は一般的に、免疫グロブリンE（IgE）レベルの上昇を伴います。アトピー性皮膚炎は、食物アレルギー、喘息、アレルギー性鼻炎を含む一連のアレルギー性疾患の中で最初に発症する疾患であり、アトピー性皮膚炎は、他の上皮バリア表面における後続のアレルギー性疾患につながる可能性のある進行の一部であるとするアトピーマーチ理論が生まれました。

アトピー性皮膚炎の主な症状は、乾燥したかゆみのある皮膚で、再燃時にはしばしば赤い発疹に変わります。多くの異なる物理的および内的要因が、湿疹の再燃の引き金となります。その結果、炎症が血流を増加させ、かゆみを引き起こします。湿疹の再燃は、痒みと掻破の苦悩のサイクルの一部です。このサイクルの原動力となる身体的・心理的要素と闘うのは困難です。掻きむしることは、その時は気持ちが良いのですが、さらに炎症を引き起こし、皮膚感染症を引き起こすことさえあります。アトピー性皮膚炎は年齢によって症状が異なります。アトピー性皮膚炎市場は、新規パイプライン医薬品の開発が急速に進んでいることから、予測期間中に大きな市場成長が見込まれています。同様に、新規生物製剤の需要増加や製品承認も、アトピー性皮膚炎市場の成長を促進すると予測されています。

さらに、新興国における有利な償還政策とアトピー性皮膚炎の高い有病率が市場成長率を牽引すると予測されます。さらに、アトピー性皮膚炎の治療法に関する認知度の向上や、より安価で優れた治療法を提供するための政府による様々な取り組みが、アトピー性皮膚炎市場の成長に影響を及ぼすと予想されます。さらに、急速な技術進歩や研究開発に対する政府支援の増加とともに、資金調達の増加は、予測期間中に市場成長のための様々な新たな機会を創出すると考えられます。
一方、適応外治療によるアレルギー反応や製品の特許切れなどは、予測期間中の対象市場の成長に影響を与える可能性があります。

アトピー性皮膚炎市場は、薬剤クラス、投与経路、流通チャネル、地域によって区分されます。
薬剤クラス別では、コルチコステロイド、カルシニューリン阻害剤、PDE4阻害剤、生物学的製剤、その他に分類されます。
投与経路別では、局所剤、注射剤、経口剤に分類されます。
エンドユーザー別では、病院薬局、小売薬局、オンライン薬局に分類されます。
地域別では、北米（米国、カナダ、メキシコ）、欧州（ドイツ、フランス、英国、イタリア、スペイン、その他欧州）、アジア太平洋（日本、中国、オーストラリア、インド、韓国、その他アジア太平洋）、LAMEA（ブラジル、南アフリカ、サウジアラビア、その他LAMEA）に市場を分けて分析しています。

北米は2021年のアトピー性皮膚炎市場で最大の市場シェアを占め、予測期間中もその優位性を維持すると予測されています。これは主に、アトピー性皮膚炎の有病率の増加、米国全域の患者層における高い治療意識、確立された医療インフラ、新規薬剤の早期採用によるものです。例えば、2022年全米湿疹協会によると、米国成人の推定アトピー性皮膚炎患者数は1,650万人（7.3%）で、2歳以上で発症し、40%近くが中等症または重症です。

本レポートでは、世界のアトピー性皮膚炎市場における主要企業を包括的に分析しています。本レポートに掲載されている主要企業には、AbbVie Inc.、Arcutis Biotherapeutics, Inc.、Asana Biosciences, Inc.、Astellas Pharma, Inc.、Bayer AG, Inc.、Bristol-Myers Squibb Inc.、Dermavant Sciences, Inc、 Eli Lilly and Company, Inc.、Galderma, Inc.、Incyte Corporation, Inc.、Leo Pharma, Inc.、Novartis AG、大塚製薬株式会社、Pfizer Inc.、Regeneron Pharmaceuticals, Inc.、Sanofi SA, Inc.、Viatris, Inc.などがあります。

〈ステークホルダーにとっての主なメリット〉
・アトピー性皮膚炎の市場機会を特定するため、2021年から2031年までのアトピー性皮膚炎市場分析の市場セグメント、現在の動向、予測、ダイナミクスを定量的に分析します。
・主な促進要因、阻害要因、機会に関する情報とともに市場調査を提供します。
・ポーターのファイブフォース分析により、バイヤーとサプライヤーの潜在力を明らかにし、ステークホルダーが利益重視のビジネス決定を行い、サプライヤーとバイヤーのネットワークを強化できるようにします。
・アトピー性皮膚炎市場のセグメンテーションを詳細に分析することで、市場機会を見極めることができます。
・各地域の主要国は、世界市場への収益貢献度に応じてマッピングされています。
・市場プレイヤーのポジショニングはベンチマーキングを容易にし、市場プレイヤーの現在のポジションを明確に理解することができます。
・アトピー性皮膚炎の地域別および世界市場動向、主要企業、市場セグメント、応用分野、市場成長戦略の分析を含みます。

〈主要市場セグメント〉
薬剤クラス別
PDE-4阻害剤
副腎皮質ステロイド薬
その他
生物製剤
カルシニューリン阻害薬

種類別
タクロリムス
ピメクロリムス

投与方法別
局所剤
注射剤
経口剤

流通経路別
病院薬局
小売薬局
オンライン薬局

地域別
・北米
アメリカ
カナダ
メキシコ
・ヨーロッパ
ドイツ
フランス
イギリス
イタリア
スペイン
その他のヨーロッパ
・アジア太平洋
日本
中国
オーストラリア
インド
韓国
その他のアジア太平洋地域
・LAMEA
ブラジル
サウジアラビア
南アフリカ
その他のLAMEA地域

〈主要市場プレイヤー〉
Sanofi SA
Novartis International AG
Bristol-Myers Squibb
Bayer AG
AbbVie Inc.
Pfizer Inc.
Astellas Pharma Inc.
Regeneron Pharmaceuticals Inc.
Arcutis Biotherapeutics
Asana Biosciences
Dermavant
Eli Lilly
Galderma
Incyte
Viatris
Leo Pharma
大塚ホールディングス株式会社

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: ATOPIC DERMATITIS MARKET, BY DRUG CLASS
4.1 Overview
4.1.1 Market size and forecast
4.2 Biologics
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Calcineurin Inhibitors
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
4.3.4 Calcineurin Inhibitors Atopic Dermatitis Market by Type
4.3.4.1 Tacrolimus Market size and forecast, by region
4.3.4.2 Pimecrolimus Market size and forecast, by region
4.4 PDE-4 Inhibitor
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market analysis by country
4.5 Corticosteroids
4.5.1 Key market trends, growth factors and opportunities
4.5.2 Market size and forecast, by region
4.5.3 Market analysis by country
4.6 Others
4.6.1 Key market trends, growth factors and opportunities
4.6.2 Market size and forecast, by region
4.6.3 Market analysis by country
CHAPTER 5: ATOPIC DERMATITIS MARKET, BY MODE OF ADMINISTRATION
5.1 Overview
5.1.1 Market size and forecast
5.2 Topical
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Injectable
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
5.4 Oral
5.4.1 Key market trends, growth factors and opportunities
5.4.2 Market size and forecast, by region
5.4.3 Market analysis by country
CHAPTER 6: ATOPIC DERMATITIS MARKET, BY DISTRIBUTION CHANNEL
6.1 Overview
6.1.1 Market size and forecast
6.2 Hospital Pharmacies
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market analysis by country
6.3 Retail Pharmacies
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market analysis by country
6.4 Online Pharmacies
6.4.1 Key market trends, growth factors and opportunities
6.4.2 Market size and forecast, by region
6.4.3 Market analysis by country
CHAPTER 7: ATOPIC DERMATITIS MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Drug Class
7.2.2.1 North America Calcineurin Inhibitors Atopic Dermatitis Market by Type
7.2.3 North America Market size and forecast, by Mode Of Administration
7.2.4 North America Market size and forecast, by Distribution Channel
7.2.5 North America Market size and forecast, by country
7.2.5.1 U.S.
7.2.5.1.1 Market size and forecast, by Drug Class
7.2.5.1.2 Market size and forecast, by Mode Of Administration
7.2.5.1.3 Market size and forecast, by Distribution Channel
7.2.5.2 Canada
7.2.5.2.1 Market size and forecast, by Drug Class
7.2.5.2.2 Market size and forecast, by Mode Of Administration
7.2.5.2.3 Market size and forecast, by Distribution Channel
7.2.5.3 Mexico
7.2.5.3.1 Market size and forecast, by Drug Class
7.2.5.3.2 Market size and forecast, by Mode Of Administration
7.2.5.3.3 Market size and forecast, by Distribution Channel
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Drug Class
7.3.2.1 Europe Calcineurin Inhibitors Atopic Dermatitis Market by Type
7.3.3 Europe Market size and forecast, by Mode Of Administration
7.3.4 Europe Market size and forecast, by Distribution Channel
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Market size and forecast, by Drug Class
7.3.5.1.2 Market size and forecast, by Mode Of Administration
7.3.5.1.3 Market size and forecast, by Distribution Channel
7.3.5.2 France
7.3.5.2.1 Market size and forecast, by Drug Class
7.3.5.2.2 Market size and forecast, by Mode Of Administration
7.3.5.2.3 Market size and forecast, by Distribution Channel
7.3.5.3 UK
7.3.5.3.1 Market size and forecast, by Drug Class
7.3.5.3.2 Market size and forecast, by Mode Of Administration
7.3.5.3.3 Market size and forecast, by Distribution Channel
7.3.5.4 Italy
7.3.5.4.1 Market size and forecast, by Drug Class
7.3.5.4.2 Market size and forecast, by Mode Of Administration
7.3.5.4.3 Market size and forecast, by Distribution Channel
7.3.5.5 Spain
7.3.5.5.1 Market size and forecast, by Drug Class
7.3.5.5.2 Market size and forecast, by Mode Of Administration
7.3.5.5.3 Market size and forecast, by Distribution Channel
7.3.5.6 Rest of Europe
7.3.5.6.1 Market size and forecast, by Drug Class
7.3.5.6.2 Market size and forecast, by Mode Of Administration
7.3.5.6.3 Market size and forecast, by Distribution Channel
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Drug Class
7.4.2.1 Asia-Pacific Calcineurin Inhibitors Atopic Dermatitis Market by Type
7.4.3 Asia-Pacific Market size and forecast, by Mode Of Administration
7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 Japan
7.4.5.1.1 Market size and forecast, by Drug Class
7.4.5.1.2 Market size and forecast, by Mode Of Administration
7.4.5.1.3 Market size and forecast, by Distribution Channel
7.4.5.2 China
7.4.5.2.1 Market size and forecast, by Drug Class
7.4.5.2.2 Market size and forecast, by Mode Of Administration
7.4.5.2.3 Market size and forecast, by Distribution Channel
7.4.5.3 Australia
7.4.5.3.1 Market size and forecast, by Drug Class
7.4.5.3.2 Market size and forecast, by Mode Of Administration
7.4.5.3.3 Market size and forecast, by Distribution Channel
7.4.5.4 India
7.4.5.4.1 Market size and forecast, by Drug Class
7.4.5.4.2 Market size and forecast, by Mode Of Administration
7.4.5.4.3 Market size and forecast, by Distribution Channel
7.4.5.5 South Korea
7.4.5.5.1 Market size and forecast, by Drug Class
7.4.5.5.2 Market size and forecast, by Mode Of Administration
7.4.5.5.3 Market size and forecast, by Distribution Channel
7.4.5.6 Rest of Asia-Pacific
7.4.5.6.1 Market size and forecast, by Drug Class
7.4.5.6.2 Market size and forecast, by Mode Of Administration
7.4.5.6.3 Market size and forecast, by Distribution Channel
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Drug Class
7.5.2.1 LAMEA Calcineurin Inhibitors Atopic Dermatitis Market by Type
7.5.3 LAMEA Market size and forecast, by Mode Of Administration
7.5.4 LAMEA Market size and forecast, by Distribution Channel
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Market size and forecast, by Drug Class
7.5.5.1.2 Market size and forecast, by Mode Of Administration
7.5.5.1.3 Market size and forecast, by Distribution Channel
7.5.5.2 Saudi Arabia
7.5.5.2.1 Market size and forecast, by Drug Class
7.5.5.2.2 Market size and forecast, by Mode Of Administration
7.5.5.2.3 Market size and forecast, by Distribution Channel
7.5.5.3 South Africa
7.5.5.3.1 Market size and forecast, by Drug Class
7.5.5.3.2 Market size and forecast, by Mode Of Administration
7.5.5.3.3 Market size and forecast, by Distribution Channel
7.5.5.4 Rest of LAMEA
7.5.5.4.1 Market size and forecast, by Drug Class
7.5.5.4.2 Market size and forecast, by Mode Of Administration
7.5.5.4.3 Market size and forecast, by Distribution Channel
CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments
CHAPTER 9: COMPANY PROFILES
9.1 Sanofi SA
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 Novartis International AG
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 Bristol-Myers Squibb
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 Bayer AG
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 AbbVie Inc.
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 Pfizer Inc.
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 Astellas Pharma Inc.
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 Regeneron Pharmaceuticals Inc.
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 Arcutis Biotherapeutics
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 Asana Biosciences
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments
9.11 Dermavant
9.11.1 Company overview
9.11.2 Company snapshot
9.11.3 Operating business segments
9.11.4 Product portfolio
9.11.5 Business performance
9.11.6 Key strategic moves and developments
9.12 Eli Lilly
9.12.1 Company overview
9.12.2 Company snapshot
9.12.3 Operating business segments
9.12.4 Product portfolio
9.12.5 Business performance
9.12.6 Key strategic moves and developments
9.13 Galderma
9.13.1 Company overview
9.13.2 Company snapshot
9.13.3 Operating business segments
9.13.4 Product portfolio
9.13.5 Business performance
9.13.6 Key strategic moves and developments
9.14 Incyte
9.14.1 Company overview
9.14.2 Company snapshot
9.14.3 Operating business segments
9.14.4 Product portfolio
9.14.5 Business performance
9.14.6 Key strategic moves and developments
9.15 Viatris
9.15.1 Company overview
9.15.2 Company snapshot
9.15.3 Operating business segments
9.15.4 Product portfolio
9.15.5 Business performance
9.15.6 Key strategic moves and developments
9.16 Leo Pharma
9.16.1 Company overview
9.16.2 Company snapshot
9.16.3 Operating business segments
9.16.4 Product portfolio
9.16.5 Business performance
9.16.6 Key strategic moves and developments
9.17 Otsuka Holdings Co.,Ltd
9.17.1 Company overview
9.17.2 Company snapshot
9.17.3 Operating business segments
9.17.4 Product portfolio
9.17.5 Business performance
9.17.6 Key strategic moves and developments

LIST OF TABLES
TABLE 1. GLOBAL ATOPIC DERMATITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 2. ATOPIC DERMATITIS MARKET, FOR BIOLOGICS, BY REGION, 2021-2031 ($MILLION)
TABLE 3. ATOPIC DERMATITIS MARKET FOR BIOLOGICS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 4. ATOPIC DERMATITIS MARKET, FOR CALCINEURIN INHIBITORS, BY REGION, 2021-2031 ($MILLION)
TABLE 5. ATOPIC DERMATITIS MARKET FOR CALCINEURIN INHIBITORS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 6. GLOBAL CALCINEURIN INHIBITORS ATOPIC DERMATITIS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 7. ATOPIC DERMATITIS MARKET, FOR TACROLIMUS, BY REGION, 2021-2031 ($MILLION)
TABLE 8. ATOPIC DERMATITIS MARKET, FOR PIMECROLIMUS, BY REGION, 2021-2031 ($MILLION)
TABLE 9. ATOPIC DERMATITIS MARKET, FOR PDE-4 INHIBITOR, BY REGION, 2021-2031 ($MILLION)
TABLE 10. ATOPIC DERMATITIS MARKET FOR PDE-4 INHIBITOR, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 11. ATOPIC DERMATITIS MARKET, FOR CORTICOSTEROIDS, BY REGION, 2021-2031 ($MILLION)
TABLE 12. ATOPIC DERMATITIS MARKET FOR CORTICOSTEROIDS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 13. ATOPIC DERMATITIS MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
TABLE 14. ATOPIC DERMATITIS MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 15. GLOBAL ATOPIC DERMATITIS MARKET, BY MODE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 16. ATOPIC DERMATITIS MARKET, FOR TOPICAL, BY REGION, 2021-2031 ($MILLION)
TABLE 17. ATOPIC DERMATITIS MARKET FOR TOPICAL, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 18. ATOPIC DERMATITIS MARKET, FOR INJECTABLE, BY REGION, 2021-2031 ($MILLION)
TABLE 19. ATOPIC DERMATITIS MARKET FOR INJECTABLE, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 20. ATOPIC DERMATITIS MARKET, FOR ORAL, BY REGION, 2021-2031 ($MILLION)
TABLE 21. ATOPIC DERMATITIS MARKET FOR ORAL, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 22. GLOBAL ATOPIC DERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 23. ATOPIC DERMATITIS MARKET, FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
TABLE 24. ATOPIC DERMATITIS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 25. ATOPIC DERMATITIS MARKET, FOR RETAIL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
TABLE 26. ATOPIC DERMATITIS MARKET FOR RETAIL PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 27. ATOPIC DERMATITIS MARKET, FOR ONLINE PHARMACIES, BY REGION, 2021-2031 ($MILLION)
TABLE 28. ATOPIC DERMATITIS MARKET FOR ONLINE PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 29. ATOPIC DERMATITIS MARKET, BY REGION, 2021-2031 ($MILLION)
TABLE 30. NORTH AMERICA ATOPIC DERMATITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 31. NORTH AMERICA CALCINEURIN INHIBITORS ATOPIC DERMATITIS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 32. NORTH AMERICA ATOPIC DERMATITIS MARKET, BY MODE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 33. NORTH AMERICA ATOPIC DERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 34. NORTH AMERICA ATOPIC DERMATITIS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 35. U.S. ATOPIC DERMATITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 36. U.S. ATOPIC DERMATITIS MARKET, BY MODE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 37. U.S. ATOPIC DERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 38. CANADA ATOPIC DERMATITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 39. CANADA ATOPIC DERMATITIS MARKET, BY MODE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 40. CANADA ATOPIC DERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 41. MEXICO ATOPIC DERMATITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 42. MEXICO ATOPIC DERMATITIS MARKET, BY MODE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 43. MEXICO ATOPIC DERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 44. EUROPE ATOPIC DERMATITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 45. EUROPE CALCINEURIN INHIBITORS ATOPIC DERMATITIS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 46. EUROPE ATOPIC DERMATITIS MARKET, BY MODE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 47. EUROPE ATOPIC DERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 48. EUROPE ATOPIC DERMATITIS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 49. GERMANY ATOPIC DERMATITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 50. GERMANY ATOPIC DERMATITIS MARKET, BY MODE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 51. GERMANY ATOPIC DERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 52. FRANCE ATOPIC DERMATITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 53. FRANCE ATOPIC DERMATITIS MARKET, BY MODE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 54. FRANCE ATOPIC DERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 55. UK ATOPIC DERMATITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 56. UK ATOPIC DERMATITIS MARKET, BY MODE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 57. UK ATOPIC DERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 58. ITALY ATOPIC DERMATITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 59. ITALY ATOPIC DERMATITIS MARKET, BY MODE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 60. ITALY ATOPIC DERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 61. SPAIN ATOPIC DERMATITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 62. SPAIN ATOPIC DERMATITIS MARKET, BY MODE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 63. SPAIN ATOPIC DERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 64. REST OF EUROPE ATOPIC DERMATITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 65. REST OF EUROPE ATOPIC DERMATITIS MARKET, BY MODE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 66. REST OF EUROPE ATOPIC DERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 67. ASIA-PACIFIC ATOPIC DERMATITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 68. ASIA-PACIFIC CALCINEURIN INHIBITORS ATOPIC DERMATITIS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 69. ASIA-PACIFIC ATOPIC DERMATITIS MARKET, BY MODE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 70. ASIA-PACIFIC ATOPIC DERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 71. ASIA-PACIFIC ATOPIC DERMATITIS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 72. JAPAN ATOPIC DERMATITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 73. JAPAN ATOPIC DERMATITIS MARKET, BY MODE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 74. JAPAN ATOPIC DERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 75. CHINA ATOPIC DERMATITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 76. CHINA ATOPIC DERMATITIS MARKET, BY MODE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 77. CHINA ATOPIC DERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 78. AUSTRALIA ATOPIC DERMATITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 79. AUSTRALIA ATOPIC DERMATITIS MARKET, BY MODE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 80. AUSTRALIA ATOPIC DERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 81. INDIA ATOPIC DERMATITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 82. INDIA ATOPIC DERMATITIS MARKET, BY MODE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 83. INDIA ATOPIC DERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 84. SOUTH KOREA ATOPIC DERMATITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 85. SOUTH KOREA ATOPIC DERMATITIS MARKET, BY MODE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 86. SOUTH KOREA ATOPIC DERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 87. REST OF ASIA-PACIFIC ATOPIC DERMATITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 88. REST OF ASIA-PACIFIC ATOPIC DERMATITIS MARKET, BY MODE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 89. REST OF ASIA-PACIFIC ATOPIC DERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 90. LAMEA ATOPIC DERMATITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 91. LAMEA CALCINEURIN INHIBITORS ATOPIC DERMATITIS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 92. LAMEA ATOPIC DERMATITIS MARKET, BY MODE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 93. LAMEA ATOPIC DERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 94. LAMEA ATOPIC DERMATITIS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 95. BRAZIL ATOPIC DERMATITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 96. BRAZIL ATOPIC DERMATITIS MARKET, BY MODE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 97. BRAZIL ATOPIC DERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 98. SAUDI ARABIA ATOPIC DERMATITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 99. SAUDI ARABIA ATOPIC DERMATITIS MARKET, BY MODE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 100. SAUDI ARABIA ATOPIC DERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 101. SOUTH AFRICA ATOPIC DERMATITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 102. SOUTH AFRICA ATOPIC DERMATITIS MARKET, BY MODE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 103. SOUTH AFRICA ATOPIC DERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 104. REST OF LAMEA ATOPIC DERMATITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 105. REST OF LAMEA ATOPIC DERMATITIS MARKET, BY MODE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 106. REST OF LAMEA ATOPIC DERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 107.SANOFI SA: COMPANY SNAPSHOT
TABLE 108.SANOFI SA: OPERATING SEGMENTS
TABLE 109.SANOFI SA: PRODUCT PORTFOLIO
TABLE 110.SANOFI SA: NET SALES,
TABLE 111.SANOFI SA: KEY STRATERGIES
TABLE 112.NOVARTIS INTERNATIONAL AG: COMPANY SNAPSHOT
TABLE 113.NOVARTIS INTERNATIONAL AG: OPERATING SEGMENTS
TABLE 114.NOVARTIS INTERNATIONAL AG: PRODUCT PORTFOLIO
TABLE 115.NOVARTIS INTERNATIONAL AG: NET SALES,
TABLE 116.NOVARTIS INTERNATIONAL AG: KEY STRATERGIES
TABLE 117.BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT
TABLE 118.BRISTOL-MYERS SQUIBB: OPERATING SEGMENTS
TABLE 119.BRISTOL-MYERS SQUIBB: PRODUCT PORTFOLIO
TABLE 120.BRISTOL-MYERS SQUIBB: NET SALES,
TABLE 121.BRISTOL-MYERS SQUIBB: KEY STRATERGIES
TABLE 122.BAYER AG: COMPANY SNAPSHOT
TABLE 123.BAYER AG: OPERATING SEGMENTS
TABLE 124.BAYER AG: PRODUCT PORTFOLIO
TABLE 125.BAYER AG: NET SALES,
TABLE 126.BAYER AG: KEY STRATERGIES
TABLE 127.ABBVIE INC.: COMPANY SNAPSHOT
TABLE 128.ABBVIE INC.: OPERATING SEGMENTS
TABLE 129.ABBVIE INC.: PRODUCT PORTFOLIO
TABLE 130.ABBVIE INC.: NET SALES,
TABLE 131.ABBVIE INC.: KEY STRATERGIES
TABLE 132.PFIZER INC.: COMPANY SNAPSHOT
TABLE 133.PFIZER INC.: OPERATING SEGMENTS
TABLE 134.PFIZER INC.: PRODUCT PORTFOLIO
TABLE 135.PFIZER INC.: NET SALES,
TABLE 136.PFIZER INC.: KEY STRATERGIES
TABLE 137.ASTELLAS PHARMA INC.: COMPANY SNAPSHOT
TABLE 138.ASTELLAS PHARMA INC.: OPERATING SEGMENTS
TABLE 139.ASTELLAS PHARMA INC.: PRODUCT PORTFOLIO
TABLE 140.ASTELLAS PHARMA INC.: NET SALES,
TABLE 141.ASTELLAS PHARMA INC.: KEY STRATERGIES
TABLE 142.REGENERON PHARMACEUTICALS INC.: COMPANY SNAPSHOT
TABLE 143.REGENERON PHARMACEUTICALS INC.: OPERATING SEGMENTS
TABLE 144.REGENERON PHARMACEUTICALS INC.: PRODUCT PORTFOLIO
TABLE 145.REGENERON PHARMACEUTICALS INC.: NET SALES,
TABLE 146.REGENERON PHARMACEUTICALS INC.: KEY STRATERGIES
TABLE 147.ARCUTIS BIOTHERAPEUTICS: COMPANY SNAPSHOT
TABLE 148.ARCUTIS BIOTHERAPEUTICS: OPERATING SEGMENTS
TABLE 149.ARCUTIS BIOTHERAPEUTICS: PRODUCT PORTFOLIO
TABLE 150.ARCUTIS BIOTHERAPEUTICS: NET SALES,
TABLE 151.ARCUTIS BIOTHERAPEUTICS: KEY STRATERGIES
TABLE 152.ASANA BIOSCIENCES: COMPANY SNAPSHOT
TABLE 153.ASANA BIOSCIENCES: OPERATING SEGMENTS
TABLE 154.ASANA BIOSCIENCES: PRODUCT PORTFOLIO
TABLE 155.ASANA BIOSCIENCES: NET SALES,
TABLE 156.ASANA BIOSCIENCES: KEY STRATERGIES
TABLE 157.DERMAVANT: COMPANY SNAPSHOT
TABLE 158.DERMAVANT: OPERATING SEGMENTS
TABLE 159.DERMAVANT: PRODUCT PORTFOLIO
TABLE 160.DERMAVANT: NET SALES,
TABLE 161.DERMAVANT: KEY STRATERGIES
TABLE 162.ELI LILLY: COMPANY SNAPSHOT
TABLE 163.ELI LILLY: OPERATING SEGMENTS
TABLE 164.ELI LILLY: PRODUCT PORTFOLIO
TABLE 165.ELI LILLY: NET SALES,
TABLE 166.ELI LILLY: KEY STRATERGIES
TABLE 167.GALDERMA: COMPANY SNAPSHOT
TABLE 168.GALDERMA: OPERATING SEGMENTS
TABLE 169.GALDERMA: PRODUCT PORTFOLIO
TABLE 170.GALDERMA: NET SALES,
TABLE 171.GALDERMA: KEY STRATERGIES
TABLE 172.INCYTE: COMPANY SNAPSHOT
TABLE 173.INCYTE: OPERATING SEGMENTS
TABLE 174.INCYTE: PRODUCT PORTFOLIO
TABLE 175.INCYTE: NET SALES,
TABLE 176.INCYTE: KEY STRATERGIES
TABLE 177.VIATRIS: COMPANY SNAPSHOT
TABLE 178.VIATRIS: OPERATING SEGMENTS
TABLE 179.VIATRIS: PRODUCT PORTFOLIO
TABLE 180.VIATRIS: NET SALES,
TABLE 181.VIATRIS: KEY STRATERGIES
TABLE 182.LEO PHARMA: COMPANY SNAPSHOT
TABLE 183.LEO PHARMA: OPERATING SEGMENTS
TABLE 184.LEO PHARMA: PRODUCT PORTFOLIO
TABLE 185.LEO PHARMA: NET SALES,
TABLE 186.LEO PHARMA: KEY STRATERGIES
TABLE 187.OTSUKA HOLDINGS CO.,LTD: COMPANY SNAPSHOT
TABLE 188.OTSUKA HOLDINGS CO.,LTD: OPERATING SEGMENTS
TABLE 189.OTSUKA HOLDINGS CO.,LTD: PRODUCT PORTFOLIO
TABLE 190.OTSUKA HOLDINGS CO.,LTD: NET SALES,
TABLE 191.OTSUKA HOLDINGS CO.,LTD: KEY STRATERGIES

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 白斑治療のグローバル市場（2021〜2031）：コルチコステロイド、カルシニューリン阻害剤、その他
  • 血管炎治療のグローバル市場（2021〜2031）：生物製剤、コルチコステロイド・免疫抑制剤
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(ALD23JN080 )"アトピー性皮膚炎のグローバル市場（2020～2030）：生物製剤、カルシニューリン阻害剤、PDE-4阻害剤、コルチコステロイド、その他" (英文：Atopic Dermatitis Market By Drug Class (Biologics, Calcineurin Inhibitors, PDE-4 Inhibitor, Corticosteroids, Others), By Mode Of Administration (Topical, Injectable, Oral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2021-2031)はAllied Market Research社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。